 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CD19/CD22 CAR T-cells / National Cancer Institute
Trial suspension: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Oct 26, 2023
P1/2, N=116, Suspended, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended
- | CD19/CD22 CAR T-cells / National Cancer Institute
Enrollment open: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Oct 24, 2023
P1/2, N=116, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Suspended Suspended --> Recruiting
- | CD19/CD22 CAR T-cells / National Cancer Institute
Trial suspension: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Sep 8, 2023
P1/2, N=146, Suspended, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Recruiting --> Suspended
- | CD19/CD22 CAR T-cells / National Cancer Institute
Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date, CAR T-Cell Therapy, Metastases, Immune cell: Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov) - Aug 21, 2023
P1/2, N=0, Withdrawn, Sponsor: M.D. Anderson Cancer Center
Recruiting --> Suspended N=30 --> 0 | Trial completion date: Aug 2023 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Nov 2022
- CD19/CD22 CAR T-cells / National Cancer Institute
Investigating Whole Blood as a Starting Material for CAR-T Cell Manufacturing (Board No. 755) - Apr 21, 2023 - Abstract #ASGCT2023ASGCT_1178;
P1
An ongoing clinical trial at the NIH Clinical Center utilizing the same CAR tested here (clinicaltrials.gov NCT03448393) has a safe and effective dose of 3x106 cells/ kg with an average patient weight of 60 kg. We show here that this therapeutic dose is attainable with a whole blood starting product given the scalability of the system and the fact that we can safely draw larger volumes of blood.
- | CD19/CD22 CAR T-cells / National Cancer Institute
Enrollment open: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Dec 29, 2022
P1/2, N=146, Recruiting, Sponsor: National Cancer Institute (NCI)
We show here that this therapeutic dose is attainable with a whole blood starting product given the scalability of the system and the fact that we can safely draw larger volumes of blood. Not yet recruiting --> Recruiting
- | CD19/CD22 CAR T-cells / National Cancer Institute
Enrollment change: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Nov 29, 2022
P1, N=140, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting N=87 --> 140
- | CD19/CD22 CAR T-cells / National Cancer Institute
Trial primary completion date, CAR T-Cell Therapy, Metastases, Immune cell: Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov) - Jul 19, 2022
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
N=87 --> 140 Trial primary completion date: Aug 2022 --> Aug 2023
- | CD19/CD22 CAR T-cells / National Cancer Institute
New P1/2 trial: CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Jul 4, 2022
P1/2, N=146, Not yet recruiting, Sponsor: National Cancer Institute (NCI)
- | CD19/CD22 CAR T-cells / National Cancer Institute
Trial completion date, Trial primary completion date: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Dec 30, 2021
P1, N=87, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Aug 2022 --> Aug 2023 Trial completion date: Dec 2032 --> Dec 2040 | Trial primary completion date: Dec 2022 --> Dec 2025
- | CD19/CD22 CAR T-cells / National Cancer Institute
Trial primary completion date: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Dec 16, 2021
P1, N=87, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Dec 2032 --> Dec 2040 | Trial primary completion date: Dec 2022 --> Dec 2025 Trial primary completion date: Dec 2021 --> Dec 2022
- | CD19/CD22 CAR T-cells / National Cancer Institute
Trial initiation date, CAR T-Cell Therapy, Metastases, Immune cell: Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov) - Jun 18, 2020
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Dec 2021 --> Dec 2022 Initiation date: Nov 2019 --> Nov 2020
- | CD19/CD22 CAR T-cells / National Cancer Institute
New P1/2 trial, CAR T-Cell Therapy, Metastases, Immune cell: Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma (clinicaltrials.gov) - Jul 22, 2019
P1/2, N=30, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | CD19/CD22 CAR T-cells / National Cancer Institute
Enrollment open: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Mar 20, 2018
P1, N=87, Recruiting, Sponsor: National Cancer Institute (NCI)
Initiation date: Nov 2019 --> Nov 2020 Not yet recruiting --> Recruiting
- | CD19/CD22 CAR T-cells / National Cancer Institute
New P1 trial: CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies (clinicaltrials.gov) - Feb 28, 2018
P1, N=87, Not yet recruiting, Sponsor: National Cancer Institute (NCI)